克罗恩病患者治疗反应对严重感染风险的影响:PYRAMID注册研究的二次分析
该研究为PYRAMID注册研究(NCT00524537)的二次分析,纳入1515例起始阿达木单抗治疗的克罗恩病患者,按治疗6个月时是否达到无激素临床缓解分为应答者与非应答者。应答者较非应答者发生严重感染的风险降低34%(HR 0.66,95%CI 0.46-0.96),胃肠道和肠外感染风险均较低。
要点
- 阿达木单抗治疗6个月达到无激素临床缓解的克罗恩病患者,后续严重感染风险较未缓解者降低34%。
- 应答者基线时中重度症状、需用激素或阿片类药物的比例均低于非应答者。
- 应答者胃肠道感染和肠外感染风险均低于非应答者。
核心结论
- 对阿达木单抗治疗有应答的克罗恩病患者,发生严重感染的风险低于无应答者。
- 这些发现强调,通过有效控制疾病和避免使用糖皮质激素,起始先进治疗可能降低克罗恩病患者严重感染的风险。
研究设计与样本
- PYRAMID注册研究(NCT00524537)的二次分析。
- 纳入1515例起始阿达木单抗治疗的克罗恩病患者。
- 以治疗起始后6个月为界标,将患者分为应答者(基于患者报告结局达到无激素临床缓解)与非应答者(未达到无激素临床缓解)。
- 采用稳定化逆概率治疗加权Cox比例风险模型,比较应答者与非应答者在治疗起始后6至36个月间的严重感染风险。
主要发现
- 1515例阿达木单抗治疗患者中,763例(50.4%)在6个月时被归类为应答者(年龄37±13岁;女性56%;病程9.5±8.5年)。
- 与非应答者相比,应答者基线时较少有中重度症状(55.6% vs 33%),较少需要激素(45.5% vs 17.3%)或阿片类药物(6.6% vs 1.3%),疾病部位、肛周疾病及既往克罗恩病并发症无差异。
- 采用稳定化逆概率治疗加权后,应答者发生严重感染的可能性较非应答者低34%(风险比0.66;95%CI 0.46-0.96)。
- 应答者胃肠道感染和肠外感染风险均低于非应答者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Traditional risk factors for serious infections with advanced therapies in patients with Crohn's disease (CD) have been assessed at baseline before starting therapy. We evaluated the impact of treatment response on the risk of serious infections in adalimumab-treated patients with CD through secondary analysis of the PYRAMID registry (NCT00524537). METHODS: We included patients with CD who initiated adalimumab and classified them as treatment responders (achieved steroid-free clinical remission based on patient-reported outcomes) vs nonresponders (not in steroid-free clinical remission) at 6 months after treatment initiation (landmark). We compared the risk of serious infections between responders vs nonresponders between 6 and 36 months after treatment initiation through stabilized inverse probability of treatment weighting Cox proportional hazards model. RESULTS: Of 1515 adalimumab-treated patients, 763 (50.4%) were classified as responders at 6 months (37 ± 13 y; 56% female; disease duration, 9.5 ± 8.5 y). Compared with nonresponders, responders were less likely to have moderate to severe symptoms (55.6% vs 33%), or require steroids (45.5% vs 17.3%) or opiates (6.6% vs 1.3%) at baseline, without any differences in disease location, perianal disease, and prior CD complications. During follow-up evaluation, using stabilized inverse probability of treatment weighting, responders were 34% less likely to experience serious infections compared with nonresponders (hazard ratio, 0.66; 95% CI, 0.46-0.96). Risk of gastrointestinal and extraintestinal infections was lower in responders vs nonresponders. CONCLUSIONS: Patients with CD who respond to adalimumab have a lower risk of developing serious infections compared with nonresponders. These findings underscore that initiation of advanced therapy for CD may lower the risk of serious infections through effective disease control and avoidance of corticosteroids.
引用
- Ahuja D, Luo J, Qi Y, et al. Impact of Treatment Response on Risk of Serious Infections in Patients With Crohn's Disease: Secondary Analysis of the PYRAMID Registry. Clin Gastroenterol Hepatol. 2024. PMID: 38216022. doi:10.1016/j.cgh.2024.01.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。